TELA - TELA Bio initiates post-market study of Ovitex for the robotic repair of ventral hernias

TELA Bio (TELA) launches a post-market study, BRAVO II, to evaluate the clinical performance of OviTex Reinforced Tissue Matrices in the robotic repair of ventral hernias.The company expects to enroll up to 100 subjects in the study at up to seven US-based sites, with patient follow-up at 90 days, 12 months, and 24 months.Study researchers will primarily monitor the incidence of early postoperative surgical site occurrences, wound-related events, and other complications within three months of surgery.

For further details see:

TELA Bio initiates post-market study of Ovitex for the robotic repair of ventral hernias